Effectiveness of pharmacological cardioversion of new-onset atrial fibrillation during thoracic surgery operations: a single-centre experience

Table 4 Intraoperative cardiovascular adverse events in timing relative to the onset of AF and pharmacological cardioversion

	5–10 min before AF			5-30 min after AF
	Non-pharmacological intervention	Pharmacological conversion	P-value	Non-pharmacological intervention	Pharmacological conversion *	P-value
Tachycardia (n, %)	8 (2.1)	5 (1.9)	0.577	26 (6.7)	0 (0)	< 0.001
Bradycardia (n, %)	0 (0)	0 (0)	-	0 (0)	4 (1.6)	0.025
Hypotension (n, %)	0 (0)	2 (0.8)	0.159	36 (9.3)	71 (27.5)	< 0.001
Mild and moderate	0 (0)	2 (0.8)	0.159	36 (9.3)	64 (24.8)	< 0.001
Severe	0 (0)	0 (0)	-	0(0)	7 (2.7)	0.002

Data are presented as n (%) of patients. AF: atrial fibrillation; Bradycardia: heart rate < 50 beats/min (bpm); Hypotension: mean blood pressure < 50mmHg; Severe hypotension: systolic pressure < 60 mmHg or mean blood pressure < 30 mmHg and need to treat urgently; Tachycardia: heart rate > 100 bpm. * Adverse events after pharmacological cardioversion agents.

ISSN: 1749-8090